Drug delivery systems (DDSs) control when and how much drugs are delivered to the body. Numerous DDS studies have been conducted but most have focused on treatments for cancer. New research from Kumamoto University uses a DDS to treat malaria.
The existing treatment for malaria is taken orally and has three main problems: most antimalarial drugs are broken down in the stomach; the drugs have strong side effects; and the medicine stays in the body for only a short time. These issues resulted in malaria treatments that were not particularly effective.
MCM-41 is a porous silica material with a pore size of 2-30 nm. It can incorporate drugs into its pores, which makes it a useful material for DDS applications. A research group headed by professor Shinya Hayami from Kumamoto University, Japan believed that MCM-41 could be used as DDS for antimalarial drugs. To test their theory, they created a new DDS by combining the antimalarial drugs Artesunate and Quinine with MCT-41 and performed in vitro and in vivo experiments. They found:
- The release time of the antimalarial medicine became very long, one week or longer, which was an improvement from the standard medication time.
- Compared to ingesting Artesunate or Quinine, the new DDS increased treatment efficiency by 20 and 240 times respectively in animal experiments. (As defined in this study, the therapeutic efficiency is 50 percent of the effective dose (ED50), and is used as an index of drug strength. The smaller the value of ED50, the greater the action of the drug. In other words, if an effect is obtained with a small amount of a drug, the treatment efficiency is high.)
- MCM-41 itself is non-toxic and inactive. A DDS using MCM-41 is expected to have very weak side effects.
"Using this DDS for antimalarial drugs has introduced a new possibility for highly efficient malaria treatment for the first time," said Hayami. "We expect that it will be put to practical use in areas where malaria treatment is still necessary. Now, we are planning to develop clinical trials for antimalarial drugs as well as new DDSs for other drugs, like anti-HIV medications."
This research was posted online in the journal Scientific Reports on Feb. 15, 2018.
Reference: Amolegbe, S. A., Hirano, Y., Adebayo, J. O., Ademowo, O. G., Balogun, E. A., Obaleye, J. A., ... Hayami, S. (2018). Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance. Scientific Reports, 8(1). doi:10.1038/s41598-018-21351-8
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.